Rose C
Dermatopathologie Lübeck, Maria-Goeppert-Str. 5, 23562, Lübeck, Deutschland.
Hautarzt. 2017 Sep;68(9):749-761. doi: 10.1007/s00105-017-4046-9.
The updated S3 guidelines on malignant melanoma were established in August 2016. The principles of diagnostics and classification are based on the histopathological results from the primary tumor and if necessary the sentinel lymph nodes. The most important factor for prognosis is the tumor thickness according to Breslow and the detection of sentinel node micrometastases. The surgical safety margin after excision is dependent on the tumor thickness. Furthermore, ulceration of the primary tumor and presence of mitosis in melanomas less than 1 mm in thickness are also considered in the T‑classification. The sentinel lymph nodes should be prepared according to established procedures using HE staining and immunohistochemical methods. The largest tumor diameter of a micrometastasis should be measured in tenths of a millimeter (Rotterdam classification). Molecular pathology testing for mutations in the BRAF and NRAS oncogenes should be carried out in patients with metastatic disease or surgically non-resectable tumors. In addition c-KIT mutations should be tested in acral lentiginous and mucosal melanomas. Treatment with signal transduction inhibitors is possible when mutations have been detected.
2016年8月制定了最新的恶性黑色素瘤S3指南。诊断和分类原则基于原发肿瘤以及必要时前哨淋巴结的组织病理学结果。预后的最重要因素是根据 Breslow 测量的肿瘤厚度以及前哨淋巴结微转移的检测情况。切除术后的手术安全切缘取决于肿瘤厚度。此外,T分类中还会考虑原发肿瘤的溃疡情况以及厚度小于1毫米的黑色素瘤中的有丝分裂情况。应按照既定程序使用苏木精-伊红染色和免疫组化方法制备前哨淋巴结。微转移灶的最大肿瘤直径应以十分之一毫米为单位测量(鹿特丹分类)。对于转移性疾病或手术不可切除肿瘤的患者,应进行BRAF和NRAS致癌基因的分子病理学检测。此外,对于肢端雀斑样痣型和黏膜黑色素瘤,应检测c-KIT突变。检测到突变时可使用信号转导抑制剂进行治疗。